Status:
RECRUITING
Predicting Outcome of Cytoreduction in Advanced Ovarian Cancer
Lead Sponsor:
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Conditions:
Ovarian Cancer Stage III
Ovarian Cancer Stage IV
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
PREDAtOOR is a pilot study and this study aims at improving the selection of the best treatment strategy for patients with advanced ovarian cancer by using Camera Vision (CV) to predict outcomes of cy...
Detailed Description
For the treatment of advanced ovarian cancer, the decision to undergo primary surgery is complex and decided by the surgeon while multiple considering multiple elements. Sometimes, chemotherapy is nee...
Eligibility Criteria
Inclusion
- Patients treated at Fondazione Policlinico Gemelli Hospital, Rome Italy, Trillium -Credit Valley Hospital, Mississauga, Ontario and Princess Margaret Cancer Centre, Toronto, Canada
- Patients fit for cytoreductive surgery
- Patients with a primary diagnosis of suspect Stage III-IV ovarian cancer
- Patients selected for interval cytoreductive surgery after NACT
Exclusion
- Patients with pre-operative Stage I-II disease confined to the pelvis
- Patients unfit for surgery
- Lack of information about patients' surgical outcomes and clinicopathological characteristics
- LGSOC, Clear cell and mucinous, non-epithelial histologic subtypes (if available)
Key Trial Info
Start Date :
January 2 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2026
Estimated Enrollment :
151 Patients enrolled
Trial Details
Trial ID
NCT06017557
Start Date
January 2 2023
End Date
September 1 2026
Last Update
December 19 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC Ginecologia Oncologica
Roma, Italy, 00168